Cyclerion Shareholders Approve Korsana Merger and 1-for-7 Reverse Split; Redomestication Rejected
CYCN has more than doubled off its 52-week low of $1.027 on elevated volume (2.7× avg).
Summary
Cyclerion shareholders approved the Korsana reverse merger and a 1-for-7 reverse stock split, but rejected the Cayman redomestication. The combined company will trade as 'KRSA' on September 9.
Key Events · M&A and Partnerships · CYCN
-
Merger and Reverse Split Approved
Shareholders approved the Korsana reverse merger, a 1-for-7 reverse stock split, and an increase in authorized shares from 400M to 700M.
-
Redomestication Rejected
The Cayman Islands redomestication proposal failed with 2,099,051 for and 1,296,575 against; the combined company will remain a Massachusetts corporation.
-
Reverse Split Details
The 1-for-7 reverse split will reduce outstanding shares from approximately 4.7M to 0.7M; authorized shares remain at 700M.
-
New Trading Identity
Post-merger, the combined company will trade on Nasdaq as 'Korsana Biosciences, Inc.' under ticker 'KRSA' starting September 9, 2026, with new CUSIP 23255M303.
Analysis · CYCN · Life Sciences
The shareholder vote clears the path for the reverse merger with Korsana Biosciences and a 1-for-7 reverse stock split, with the combined company set to trade as 'KRSA' on September 9. The rejection of the Cayman Islands redomestication means the combined company will remain a Massachusetts corporation, a governance detail that does not block the merger. With only $1.4M in cash and a going concern warning, this vote was existential for Cyclerion — the merger is the company's lifeline.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.9% of the 1612 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYCN was trading at $4.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7M. The 52-week trading range was $1.03 to $8.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.